WX-293 is a highly selective urokinase-type plasminogen activator ( uPA ) inhibitor with a K i value of 2.4 μM. WX-293 abolishes hypoxia-induced keratinocyte migration and in vitro wound closure. WX-293 can be used in research on hypoxia-mediated skin wounds and solid malignant tumors.
Products | Products > Disease Areas > Cancer | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Ser/Thr Protease
Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.